These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

106 related articles for article (PubMed ID: 29691083)

  • 1. Re: Apalutamide Treatment and Metastasis-free Survival in Prostate Cancer.
    Heinrich D; Russnes KM; Oldenburg J
    Eur Urol; 2018 Aug; 74(2):236-237. PubMed ID: 29691083
    [No Abstract]   [Full Text] [Related]  

  • 2. Re: Apalutamide Treatment and Metastasis-free Survival in Prostate Cancer.
    Haidl F; Heidenreich A; Pfister D
    Eur Urol; 2018 Aug; 74(2):237-238. PubMed ID: 29653884
    [No Abstract]   [Full Text] [Related]  

  • 3. Apalutamide and Metastasis-free Survival in Prostate Cancer.
    Rachner TD; Tsourdi E; Hofbauer LC
    N Engl J Med; 2018 Jun; 378(26):2541-2. PubMed ID: 29952180
    [No Abstract]   [Full Text] [Related]  

  • 4. Apalutamide and Metastasis-free Survival in Prostate Cancer.
    Smith MR; Yu MK; Small EJ
    N Engl J Med; 2018 Jun; 378(26):2542. PubMed ID: 29949495
    [No Abstract]   [Full Text] [Related]  

  • 5. Filling a True Unmet Need: A New Therapy for Nonmetastatic Castrate-resistant Prostate Cancer Commentary on: Apalutamide Treatment and Metastasis-free Survival in Prostate Cancer.
    Kesch C; Black PC
    Urology; 2018 Jun; 116():1-2. PubMed ID: 29596865
    [No Abstract]   [Full Text] [Related]  

  • 6. Apalutamide for Metastatic, Hormone-Responsive Prostate Cancer.
    Klotz L
    N Engl J Med; 2019 Jul; 381(1):84-86. PubMed ID: 31269371
    [No Abstract]   [Full Text] [Related]  

  • 7. Apalutamide (Erleada) for prostate cancer.
    Med Lett Drugs Ther; 2018 Jul; 60(1551):e124-e125. PubMed ID: 30036351
    [No Abstract]   [Full Text] [Related]  

  • 8. Apalutamide: the established and emerging roles in the treatment of advanced prostate cancer.
    Dellis AE; Papatsoris AG
    Expert Opin Investig Drugs; 2018 Jun; 27(6):553-559. PubMed ID: 29856649
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Re: Apalutamide for Metastatic, Castration-Sensitive Prostate Cancer.
    Taneja SS
    J Urol; 2019 Oct; 202(4):661. PubMed ID: 31294666
    [No Abstract]   [Full Text] [Related]  

  • 10. [Phase III study for local or locally advanced prostate cancer : Randomized, double-blind, placebo-controlled phase 3 study of apalutamide in patients with local high-risk prostate cancer or locally advanced prostate cancer receiving primary radiotherapy (ATLAS) - study AP 90/15 of the AUO].
    Rexer H; Graefen M
    Urologe A; 2017 Feb; 56(2):243-244. PubMed ID: 28144693
    [No Abstract]   [Full Text] [Related]  

  • 11. Neoadjuvant degarelix with or without apalutamide followed by radical prostatectomy for intermediate and high-risk prostate cancer: ARNEO, a randomized, double blind, placebo-controlled trial.
    Tosco L; Laenen A; Gevaert T; Salmon I; Decaestecker C; Davicioni E; Buerki C; Claessens F; Swinnen J; Goffin K; Oyen R; Everaerts W; Moris L; De Meerleer G; Haustermans K; Joniau S;
    BMC Cancer; 2018 Apr; 18(1):354. PubMed ID: 29606109
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Editorial Comment to Apalutamide for metastatic, castration-sensitive prostate cancer in the Japanese population: A subgroup analysis of the randomized, double-blind, placebo-controlled phase 3 TITAN study.
    Sakamoto S
    Int J Urol; 2021 Mar; 28(3):288. PubMed ID: 33327040
    [No Abstract]   [Full Text] [Related]  

  • 13. Safety and Antitumor Activity of Apalutamide (ARN-509) in Metastatic Castration-Resistant Prostate Cancer with and without Prior Abiraterone Acetate and Prednisone.
    Rathkopf DE; Antonarakis ES; Shore ND; Tutrone RF; Alumkal JJ; Ryan CJ; Saleh M; Hauke RJ; Bandekar R; Maneval EC; de Boer CJ; Yu MK; Scher HI
    Clin Cancer Res; 2017 Jul; 23(14):3544-3551. PubMed ID: 28213364
    [No Abstract]   [Full Text] [Related]  

  • 14. [New treatment option-apalutamide for nonmetastatic, castration-resistant prostate cancer].
    Hadaschik B; Panic A
    Urologe A; 2018 Jun; 57(6):729-730. PubMed ID: 29789876
    [No Abstract]   [Full Text] [Related]  

  • 15. Design, synthesis, and biological evaluation of deuterated apalutamide with improved pharmacokinetic profiles.
    Pang X; Wang Y; Chen Y
    Bioorg Med Chem Lett; 2017 Jun; 27(12):2803-2806. PubMed ID: 28478926
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Metastasis-free Survival - A New End Point in Prostate Cancer Trials.
    Beaver JA; Kluetz PG; Pazdur R
    N Engl J Med; 2018 Jun; 378(26):2458-2460. PubMed ID: 29949489
    [No Abstract]   [Full Text] [Related]  

  • 17. A novel dried blood spot LC-MS/MS method for the quantification of apalutamide in mouse whole blood: Application to pharmacokinetic study in mice.
    Saini NK; Sulochana SP; Kiran V; Zainuddin M; Mullangi R
    Biomed Chromatogr; 2018 Nov; 32(11):e4344. PubMed ID: 30006946
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Validation of an LC-ESI-MS/MS method for the determination of apalutamide, a novel non-steroidal anti-androgen in mice plasma and its application to a pharmacokinetic study in mice.
    Hallur G; Purra BR; Sulochana SP; Saini NK; Daram P; Zainuddin M; Mullangi R
    J Pharm Biomed Anal; 2018 May; 153():260-266. PubMed ID: 29518645
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Quality of life considerations in the treatment of metastatic hormone-sensitive prostate cancer.
    Chambers SK; Frydenberg M; Dunn J
    Lancet Oncol; 2019 Nov; 20(11):1469-1471. PubMed ID: 31578172
    [No Abstract]   [Full Text] [Related]  

  • 20. Structure-activity relationship for thiohydantoin androgen receptor antagonists for castration-resistant prostate cancer (CRPC).
    Jung ME; Ouk S; Yoo D; Sawyers CL; Chen C; Tran C; Wongvipat J
    J Med Chem; 2010 Apr; 53(7):2779-96. PubMed ID: 20218717
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 6.